Sartorius Stedim Biotech Acquires BioOutsource
The acquisition expands Sartorius Stedim Biotech’s service portfolio.
Sartorius Stedim Biotech (SSB), a supplier for the biopharmaceutical industries, has acquired BioOutsource, a CRO based in Glasgow, United Kingdom. This move expands SSB’s portfolio with the addition of contract testing services to support biopharmaceutical clients and help fast-track biologics through the development pipeline as well as facilitate lot release testing in large-scale manufacturing.
BioOutsource recorded EUR9 million in revenue over the past 12 months. The privately owned Scottish company, which employs approximately 85 staff, has been operating in the biotech space since 2007. It provides contract testing services to the biopharmaceutical industry, including assays to monitor the safety and quality of biologic products. BioOutsource’s services are used in early stage drug development for characterization, comparability, and lot release testing of biotherapeutics.
Details of the transaction were not disclosed.
Source: Sartorius Stedim Biotech
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
